These results suggest that the high level of ROS is needed for tumorigenesis and progression in tumors with the low HSP60 expression and HSP60 is a potential diagnostic biomarker as well as a therapeutic target in ccRCC. This evidence concerns the gene HSPD1 and nonpapillary renal cell carcinoma.